阿司帕坦乙酰舒泛 | 106372-55-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 阿司帕坦乙酰舒泛
• 中文别名: 乙酰舒泛-阿司帕坦盐
• 英文名称: Aspartame Acesulfame
• 英文别名: (3S)-3-amino-4-[[(2S)-1-methoxy-1-oxo-3-phenylpropan-2-yl]amino]-4-oxobutanoic acid;6-methyl-2,2-dioxooxathiazin-4-one
• CAS: 106372-55-8
• 化学式: C18H23O9N3S
• 分子量: 457.5
• InChiKey: KVHQNWGLVVERFR-ACMTZBLWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.39
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  207
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• [EN] COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS<br/>[FR] COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES POUR TRAITER DES TROUBLES ASSOCIÉS AUX RÉCEPTEURS 5-HT1A ET 5-HT2A
  申请人：ACHE LAB FARMACEUTICOS SA

  公开号：WO2012037634A1

  公开（公告）日：2012-03-29

  This invention is related to the alkyl-piperazine-phenyl 4 (3H)-quinazolinones general formula (I) compounds, pharmacologicaly active and able to act on the 5-HT1A and 5-HT2A serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors.

  这项发明涉及与烷基-哌嗪基苯基4(3H)-喹唑啉酮通式(I)化合物相关，这些化合物在药理学上活跃，并能通过促进对5-HT1A和5-HT2A 5-羟色胺受体的作用来控制、缓解或治疗与这些受体相关的疾病，并且含有这些化合物的药物组合物用于治疗与这些受体相关的疾病。这些化合物及其药物组合物在治疗抑郁症、焦虑症、恐惧症、成瘾、攻击性、冲动性、恐慌、精神病、进食和睡眠障碍、强迫症和女性性功能障碍等疾病方面具有用处，这些疾病与这些受体有关。
• Organic compounds
  申请人：Givaudan S.A.

  公开号：US10836712B2

  公开（公告）日：2020-11-17

  A flavour composition comprising a compound according to the formula (I) or edible salts thereof, wherein R1 is an alkyl residue containing 6 to 20 carbon atoms, or an alkene residue containing from 9 to 25 carbon atoms with 1 to 6 double bonds, R1 together with the carbonyl group to which it is attached is a residue of a carboxylic acid, and NR2R3, in which R3 is H or together with R2 and the N-atom to which they are attached, a 5-membered ring, is a residue of an amino acid, in particular a proteinogenic amino acid, ornithine, gamma-aminobutyric acid or beta alanine, or a 1-amino cycloalkyl carboxylic acid.

  一种包含符合式(I)的化合物或其可食用盐的风味组合物，其中R1是含有6至20个碳原子的烷基残基，或者含有9至25个碳原子且具有1至6个双键的烯烃残基，R1与其连接的羰基一起是羧酸的残基，NR2R3中，R3为H或与R2和它们连接的N原子一起是一个5元环的残基，是一种氨基酸的残基，特别是一种蛋白质原性氨基酸、鸟氨酸、γ-氨基丁酸或β-丙氨酸，或者是一种1-氨基环烷基羧酸的残基。
• Organic Compounds having Taste-Modifying Properties
  申请人：GIVAUDAN SA

  公开号：US20210147345A1

  公开（公告）日：2021-05-20

  This disclosure relates to flavour modification and to compounds of formula (I) or edible salts thereof, wherein R 1 is selected from C 6 -C 20 alkyl, and C 9 -C 25 alkenyl, and i) R 3 and R 4 are hydrogen and R 2 the residue of a proteinogenic amino acid; ii) R 2 and R 3 are methyl and R 4 is hydrogen; or R 4 is hydrogen and R 2 and R 3 form together with the carbon atom to which they are attached cyclopropyl; iii) R 2 is hydrogen, and R 3 and R 4 together are —CH 2 —CH 2 —CH 2 — useful in modifying flavours.

  本公开涉及风味改良以及式（I）的化合物或其可食用盐，其中R1选自C6-C20烷基和C9-C25烯基，且i）R3和R4为氢，R2为蛋白质原性氨基酸的残基；ii）R2和R3为甲基，R4为氢；或R4为氢，R2和R3与它们连接的碳原子形成环丙基；iii）R2为氢，R3和R4一起为—CH2— — —，有益于改良风味。
• Compounds and Pharmaceutical Compositions for Treating Disorders Associated With the 5-HT1A and 5-HT2A Receptors
  申请人：ACHÉ INTERNATIONAL (BVI) LTD.

  公开号：US20140303179A1

  公开（公告）日：2014-10-09

  This invention is related to the alkyl-piperazine-phenyl 4 (3H)-quinazolinones general formula (I) compounds, pharmacologicaly active and able to act on the 5-HT 1A and 5-HT 2A serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors.

  本发明涉及烷基哌嗪苯基4（3H）-喹唑啉酮通式（I）化合物，这些化合物具有药理活性，并能够通过促进对5-HT1A和5-HT2A血清素受体的作用，有助于控制、缓解或治愈与这些受体相关的疾病，以及包含这些化合物的制药组合物，用于治疗与这些受体相关的疾病。这些化合物及其制药组合物在治疗抑郁症、焦虑症、恐惧症、成瘾、攻击性、冲动性、惊恐症、精神病、进食和睡眠障碍、强迫症以及女性性功能障碍等与这些受体相关的疾病方面具有用途。
• COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING DISORDERS ASSOCIATED WITH THE 5-HT1A AND 5-HT2A RECEPTORS
  申请人：Freire Torres Russo Valter

  公开号：US20130184286A1

  公开（公告）日：2013-07-18

  This invention is related to the alkyl-piperazine-phenyl 4 (3H)-quinazolinones general formula (I) compounds, pharmacologically active and able to act on the 5-HT1A and 5-HT2A serotonin receptors in a manner that promotes the control, relief or cure of disorders associated with these receptors, and pharmaceutical compositions containing the compounds for the treatment of disorders associated with these receptors. These compounds and their pharmaceutical compositions are useful in the treatment of conditions such as depression, anxiety, phobias, addictions, aggressiveness, impulsiveness, panic, psychotic, eating and sleep disorders, obsessive-compulsive disorder and female sexual dysfunctions, among other disorders associated with these receptors.

  本发明涉及烷基哌嗪苯4(3H)-喹唑酮通式(I)化合物，这些化合物具有药理活性，并能够以促进对5-HT1A和5-HT2A血清素受体的作用来控制、缓解或治愈与这些受体相关的疾病，并且包含这些化合物的制药组合物可用于治疗与这些受体相关的疾病。这些化合物及其制药组合物在治疗抑郁症、焦虑症、恐惧症、成瘾、攻击性、冲动、惊恐、精神病、进食和睡眠障碍、强迫症和女性性功能障碍等与这些受体相关的其他疾病方面非常有用。